GLEN ALLEN, Va., April 30, 2014 /PRNewswire/ -- Star Scientific,
Inc., (NASDAQ: STSI) announced that the Company has retained
Shareholder Intelligence Services, LLC ("ShareIntel"), a provider
of stock surveillance services and applications, to obtain,
aggregate, track and analyze shareholder trading information on the
Company. Through ShareIntel's patented, proprietary service
offerings, Star Scientific is able to obtain share trading
analytic metrics that are designed to help coordinate,
monitor and enhance corporate governance, shareholder
communication, regulatory compliance, and surveillance of trading
in STSI shares.
Michael J. Mullan, MBBS (M.D.)
Ph.D, Star Scientific's Chairman and CEO, said, "We believe it is
very beneficial to our stockholders to insure that the trading
behavior of our stock is monitored, accounted for, and reviewed.
Our partnership with ShareIntel is allowing us to quantify a
significant amount of data, providing us an avenue for
appropriate action, as necessary."
The Company believes that partnering with ShareIntel is just one
initiative that will help protect shareholder value by allowing the
Company to better monitor trading activity, including potential
violations of SEC Regulation SHO, which governs stock and option
share locate, close out, and fail to deliver requirements.
Certain statements contained in this release constitute
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Such statements include,
but are not limited to statements identified by words such as
"believes," "expects," "anticipates," "estimates," "intends,"
"plans," "targets," "projects" and similar expressions. The
statements in this release are based upon the current beliefs and
expectations of our company's management and are subject to
significant risks and uncertainties. Actual results may differ from
those set forth in the forward-looking statements. Numerous factors
could cause or contribute to such differences, including, but not
limited to, results of clinical trials and/or other studies, the
challenges inherent in new product development initiatives,
including the continued development and market acceptance of our
nutraceutical dietary supplements products, the effect of any
competitive products, our ability to license and protect our
intellectual property, our ability to raise additional capital in
the future that is necessary to maintain our business, changes in
government policy and/or regulation, potential litigation by or
against us, any governmental review of our products or practices
and the outcome of the ongoing investigations as well as other
risks discussed from time to time in our filings with the
Securities and Exchange Commission, including, without limitation,
our annual report on Form 10-K for the fiscal year ended
December 31, 2013 filed on
March 17, 2014. We undertake no
duty to update any forward-looking statement or any information
contained in this press release or in other public disclosures at
any time.
About Star Scientific
Star Scientific, Inc., through its wholly owned subsidiary, Rock
Creek Pharmaceuticals, is a technology oriented company principally
focused on the discovery, development and commercialization of new
drugs, formulations and compounds that provide therapies for
inflammatory conditions, clinical immunology, neurological disease
and behavioral health. Additionally, Star Scientific is
engaged in the manufacturing, sale, and marketing of nutraceutical
dietary supplements designed to promote maintenance of a healthy
metabolism and lifestyle.
For more information, visit: http://www.starscientific.com
CONTACT:
Ted Jenkins
Vice President, Corporate Strategy, Development, Investor
Relations
Rock Creek Pharmaceuticals
(202) 887-5100
tjenkins@rockcreekpharma.com
SOURCE Star Scientific, Inc.